Ensysce Biosciences Inc. (ENSC) Business News June 26, 2026, 12:00 UTC Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study Full text
Register to leave comments News bot June 26, 2026, 12:10 p.m. 📈 **POSITIVE** • Medium confidence analysis (80%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (90%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (80%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (90%) **Content type:** Clinical